Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 1:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 559 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: cetuximab Clear all
Terminated Phase 2 Interventional Results available

Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer

NCT00551759
View directory record Official record
Conditions
Esophageal Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Cetuximab, Docetaxel, Surgery, Radiotherapy
Drug · Procedure · Radiation
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
109
States / cities
Lewes, Delaware • Newark, Delaware • Aurora, Illinois + 77 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2023 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Early Phase 1 Interventional

Pilot Study of Imatinib Cetuximab Combo for H & N Cancer

NCT05816785
View directory record Official record
Conditions
Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Interventions
Cetuximab, Imatinib
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional

NC-6004 With 5-FU and Cetuximab for Treatment of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT03109158
View directory record Official record
Conditions
Carcinoma, Squamous Cell of Head and Neck
Interventions
NC-6004, Cetuximab, 5-FU
Drug
Lead sponsor
NanoCarrier Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2019 · Synced Oct 25, 2026, 1:52 AM EDT
Completed No phase listed Observational Results available

Histological Characterization and Differentiation of Rash From Other Epidermal Growth Factor Receptor (EGFR) Inhibitors

NCT00709878
View directory record Official record
Conditions
Skin Rash
Interventions
Skin Biopsy of Skin Rash Secondary to EGFRI Use
Procedure
Lead sponsor
Northwestern University
Other
Eligibility
Not listed
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 17, 2015 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Temsirolimus With or Without Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck Cancer Who Did Not Respond to Previous Therapy

NCT01256385
View directory record Official record
Conditions
Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Salivary Gland Squamous Cell Carcinoma, Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary, Stage IV Hypopharyngeal Squamous Cell Carcinoma, Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma, Stage IVA Laryngeal Squamous Cell Carcinoma, Stage IVA Laryngeal Verrucous Carcinoma, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Oral Cavity Verrucous Carcinoma, Stage IVA Oropharyngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Squamous Cell Carcinoma, Stage IVB Laryngeal Verrucous Carcinoma, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVB Major Salivary Gland Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVB Oral Cavity Verrucous Carcinoma, Stage IVB Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Verrucous Carcinoma, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma, Stage IVC Major Salivary Gland Carcinoma, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage IVC Oral Cavity Verrucous Carcinoma, Stage IVC Oropharyngeal Squamous Cell Carcinoma, Tongue Carcinoma
Interventions
Cetuximab, Laboratory Biomarker Analysis, Temsirolimus
Biological · Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
23
States / cities
Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT01437449
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
Docetaxel, Cisplatin, Cetuximab, Carboplatin
Drug
Lead sponsor
Stanford University
Other
Eligibility
16 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
2
States / cities
Davis, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 1 Interventional

Bevacizumab in Multiple Phase I Combinations

NCT00543504
View directory record Official record
Conditions
Advanced Cancer
Interventions
Bevacizumab, Sorafenib, Erlotinib, Trastuzumab, Lapatinib, Sunitinib, Cetuximab
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Radiation and Cetuximab Plus Intratumoral EGFR Antisense DNA in Locally Advanced Head and Neck Squamous Cell Carcinoma

NCT01592721
View directory record Official record
Conditions
Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
EGFR Antisense DNA
Biological
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 25, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional Results available

Individualized Drug Treatment for Treating Patients With Pancreatic Cancer

NCT00276744
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
cetuximab, capecitabine, docetaxel, Erlotinib, Gemcitabine, Irinotecan, mitomycin C, rapamycin, conventional surgery
Biological · Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional

Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Advanced Stage III or Stage IV Head and Neck Cancer

NCT00005814
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, cisplatin, radiation therapy
Biological · Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Cetuximab, Paclitaxel, Carboplatin & Radiation for Esoph, Gastroesoph & Gastric Cancer

NCT00439608
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
Cetuximab,Paclitaxel, Carboplatin
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Feb 17, 2020 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver

NCT03366155
View directory record Official record
Conditions
Colorectal Cancer, Liver Metastases, Colorectal Adenocarcinoma, Colorectal Cancer With Hepatic Metastases, Colorectal Carcinoma
Interventions
Codman 3000 constant flow pump catheter, Panitumumab, FUDR-Dex, Oxaliplatin, 5FU, Irinotecan, HAIP installation, cetuximab, Medtronic SynchroMed II Pump, Floxuridine, Dexamethasone, EKG, CT C/A/P, CT Angiogram (abdomen), Tumor and normal liver biopsy, Leucovorin
Device · Drug · Procedure + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 25, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab-IRDye 800CW and Intraoperative Imaging in Finding Pancreatic Cancer in Patients Undergoing Surgery

NCT02736578
View directory record Official record
Conditions
Pancreatic Adenocarcinoma
Interventions
Cetuximab-IRDye800, Cetuximab
Drug
Lead sponsor
Eben Rosenthal
Other
Eligibility
19 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 25, 2026, 1:52 AM EDT
Terminated Phase 3 Interventional

Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III or Stage IV Cancer of the Oropharynx, Hypopharynx, or Larynx

NCT00004227
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cetuximab, conventional surgery, radiation therapy
Biological · Procedure · Radiation
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
3
States / cities
Lakewood, New Jersey • Long Branch, New Jersey • Somerville, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 25, 2026, 1:52 AM EDT
Terminated Phase 3 Interventional Results available

Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy

NCT00499369
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Colon Cancer, Stage IVB Rectal Cancer
Interventions
irinotecan hydrochloride, leucovorin calcium, fluorouracil, cetuximab, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
382
States / cities
Fort Smith, Arkansas • Burbank, California • Castro Valley, California + 259 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors

NCT04349267
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
BMS-986315, nivolumab, cetuximab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
2
States / cities
Sioux Falls, South Dakota • Germantown, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of Cetuximab (ERBITUX) and Concurrent Carboplatin, Paclitaxel & Radiotherapy in the Management of Patients With Advanced Locoregional Squamous Cell Carcinomas of the Head and Neck (GCC 0442)

NCT00343083
View directory record Official record
Conditions
Cancer of Head and Neck
Interventions
Erbitux, Paclitaxel & Carboplatin, Radiation
Drug · Radiation
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 25, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional Results available

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

NCT00326911
View directory record Official record
Conditions
Metastatic Pancreatic Cancer
Interventions
cetuximab, bevacizumab, gemcitabine
Biological · Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
16
States / cities
Jonesboro, Arkansas • San Francisco, California • Stamford, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 25, 2011 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

NCT01719380
View directory record Official record
Conditions
Colorectal Cancer
Interventions
LGX818, Cetuximab, BYL719
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
32
States / cities
Los Angeles, California • Santa Monica, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2021 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

NCT04616196
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Colorectal Cancer
Interventions
NKTR-255, Cetuximab
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
6
States / cities
San Diego, California • San Francisco, California • Minneapolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2025 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Phase 2 Interventional Results available

Safety And Efficacy Study Of Palbociclib Plus Cetuximab Versus Cetuximab To Treat Head And Neck Cancer

NCT02499120
View directory record Official record
Conditions
Squamous Cell Carcinoma of the Head and Neck (SCCHN)
Interventions
palbociclib, Cetuximab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
14
States / cities
La Jolla, California • San Diego, California • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2023 · Synced Oct 25, 2026, 1:52 AM EDT
Terminated Phase 2 Interventional Results available

S0414 Cetuximab, Combo Chemo, and RT in Locally Advanced Esophageal Cancer

NCT00109850
View directory record Official record
Conditions
Esophageal Cancer
Interventions
cetuximab, cisplatin, irinotecan hydrochloride, radiation therapy
Biological · Drug · Radiation
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
132
States / cities
Mobile, Alabama • Little Rock, Arkansas • Berkeley, California + 84 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2015 · Synced Oct 25, 2026, 1:52 AM EDT
Completed Early Phase 1 Interventional

Intratumoral Microdosing of TAK-981 in Head and Neck Cancer

NCT04065555
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
TAK-981, Cetuximab, Avelumab, TAK-981 + Cetuximab, TAK-981 + Avelumab
Drug · Biological · Combination Product
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • North New Hyde Park, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2022 · Synced Oct 25, 2026, 1:52 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell Carcinoma

NCT07768189
View directory record Official record
Conditions
Oropharyngeal Carcinoma (OPC)
Interventions
CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel
Drug
Lead sponsor
Corbus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
38
States / cities
Huntsville, Alabama • Tucson, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 25, 2026, 1:52 AM EDT